Navigation Links
New method for making human-based gelatin
Date:7/13/2011

Scientists are reporting development of a new approach for producing large quantities of human-derived gelatin that could become a substitute for some of the 300,000 tons of animal-based gelatin produced annually for gelatin-type desserts, marshmallows, candy and innumerable other products. Their study appears in ACS's Journal of Agriculture and Food Chemistry.

Jinchun Chen and colleagues explain that animal-based gelatin, which is made most often from the bones and skin of cows and pigs, may carry a risk of infectious diseases such as "Mad Cow" disease and could provoke immune system responses in some people. Animal-based gelatin has other draw-backs, with variability from batch to batch, for instance, creating difficulties for manufacturers. Scientists thus have sought alternatives, including development of a human-recombinant gelatin for potential use in drug capsules and other medical applications.

To get around these difficulties, the scientists developed and demonstrated a method where human gelatin genes are inserted into a strain of yeast, which can produce gelatin with controllable features. The researchers are still testing the human-yeast gelatin to see how well it compares to other gelatins in terms of its viscosity and other attributes. Chen and colleagues suggest that their method could be scaled up to produce large amounts of gelatin for commercial use.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Scientists develop method to determine order of mutations that lead to cancer
2. New non-destructive method to estimate leaf area index in vegetables
3. Researchers improve method for finding genetic mistakes that fuel cancer
4. NYU researchers outline method for DNA computation in new book
5. Yale scientists discover new method for engineering human tissue regeneration
6. Columbia engineers develop new method to diagnose heart arrhythmias
7. Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference
8. Several baffling puzzles in protein molecular structure solved with new method
9. New method for measuring biomass reveals fish stocks are more stable than widely believed
10. UC Riverside entomologists propose pesticide-free method to increase egg production
11. Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: